Concepedia

Ben Bolaños

BB

17

Publications

1.2K

Citations

15

H-Index

2003

Active since

Affiliations

Pfizer (United States)(Current)

Ben Bolaños is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

2003–2022

17

Publications

17

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Phillip A. Schwartz, Petr Kuzmič, James Solowiej et al. · Proceedings of the National Academy of Sciences · 2013 · 271 citations · Full text

Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

S.E. Greasley, Stephen Noell, Olga Plotnikova et al. · Journal of Biological Chemistry · 2022 · 168 citations · Full text

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

Alexei Brooun, K.S. Gajiwala, Ya‐Li Deng et al. · Nature Communications · 2016 · 158 citations · Full text

Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A

Casey L. Quinlan, Stephen E. Kaiser, Ben Bolaños et al. · Nature Chemical Biology · 2017 · 128 citations

, , +6

Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2

Yicheng Long, Ben Bolaños, Lihu Gong et al. · eLife · 2017 · 98 citations · Full text

Rows per page

1–5 of 17